Human Growth Hormone/administration & dosage/adverse effects/analogs & derivatives/therapeutic use; Humans; Insulin-Like Growth Factor I/metabolism; International Cooperation; Internet; Liver Function Tests; Male; Middle Aged; Pituitary Neoplasms/complications/metabolism; Receptors, Somatotropin/antagonists & inhibitors; Registries; Severity of Illness Index; United States; Young Adult
Abstract :
[en] Context Pegvisomant (Somavert, Pfizer Inc.) is the first and only available GH receptor antagonist. ACROSTUDY is an international surveillance study that offers inclusion in a web-based registry to all patients with acromegaly treated with pegvisomant; it aims at monitoring long-term safety and efficacy of this compound. Patients and methods This report summarizes the main baseline characteristics of this particular population of patients. In February 2009, over 300 centres in 10 countries had contributed 792 patients. A gradual increase in cumulative patient recruitment was observed since the launching of ACROSTUDY in 2004: from 116 patients in 2005, it steeply increased to 792 at the latest data freeze in February 2009. At the time of enrolment, 91.8% of patients were already treated with pegvisomant but baseline was considered at the time of pegvisomant start. IGF1 concentrations were measured at local laboratories. Results Of all patients, 80% were reported to have had surgery and 33% to have received radiation therapy. Of the 792 patients, 14% had received no prior medical treatment before pegvisomant start, 65.9% had received somatostatin analogues and 18.6% dopamine agonists. Interestingly, 66.7% had received only pegvisomant at study start, while it was taken in association with dopamine agonists in 5.7%, with somatostatin analogues in 23.4% and with both types of agents in 3.8%. Mean IGF1 at baseline was 522 ng/ml. Conclusion Analysis of the baseline features of these patients treated with pegvisomant and reported in the ACROSTUDY database underscores the severity of the disease in this subset of the population of patients with acromegaly previously unresponsive to several medical, surgical or radiation treatment approaches.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Brue, Thierry
Castinetti, Frederic
Lundgren, Frida
Koltowska-Haggstrom, Maria
PETROSSIANS, Patrick ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'endocrinologie clinique
Language :
English
Title :
Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY.
Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ & Lombardi G. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. European Journal of Endocrinology 2006 154 467-477.
Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF & Davis RJ. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. New England Journal of Medicine 2000 342 1171-1177. (Pubitemid 30211048)
van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA & Thorner MO. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001 358 1754-1759. (Pubitemid 33152999)
Marazuela M, Lucas T, Alvarez-Escola C, Puig-Domingo M, de la Torre NG, de Miguel-Novoa P, Duran-Hervada A, Manzanares R, Luque-Ramirez M, Halperin I, Casanueva FF & Bernabeu I. Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy. European Journal of Endocrinology 2009 160 535-542.
Brue T. ACROSTUDY: status update on 469 patients. Hormone Research 2009 71 34-38.
Trainer PJ. ACROSTUDY: an overview. Hormone Research 2007 68 68-69.
Trainer PJ. ACROSTUDY: the first 5 years. European Journal of Endocrinology 2009 161 S19-S24.
Riis P. Thirty years of bioethics: the Helsinki Declaration 1964-2003. New Review of Bioethics 2003 1 15-25.
Bex M, Abs R, T'Sjoen G, Mockel J, Velkeniers B, Muermans K & Maiter D. AcroBel - the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects. European Journal of Endocrinology 2007 157 399-409.
Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, Gomez JM, Halperin I, Lucas-Morante T, Moreno B, Obiols G, de Pablos P, Paramo C, Pico A, Torres E, Varela C, Vazquez JA, Zamora J, Albareda M & Gilabert M. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). European Journal of Endocrinology 2004 151 439-446. (Pubitemid 39430260)
ReinckeM, Petersenn S, Buchfelder M, Gerbert B, Skrobek-Engel G, Franz H, Lohmann R & Quabbe HJ. The German Acromegaly Registry: description of the database and initial results. Experimental and Clinical Endocrinology and Diabetes 2006 114 498-505. (Pubitemid 44870898)
Castinetti F, Morange I, Dubois N, Albarel F, Conte-Devolx B, Dufour H & Brue T. Does first-line surgery still have its place in the treatment of acromegaly? Annales d'Endocrinologie 2009 70 107-112.
Castinetti F, Morange I, Dufour H, Regis J & Brue T. Radiotherapy and radiosurgery in acromegaly. Pituitary 2009 12 3-10.
Chanson P. Acromegaly. Presse Médicale 2009 38 92-102.
Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K & Giustina A. Guidelines for acromegaly management: an update. Journal of Clinical Endocrinology and Metabolism 2009 94 1504-1517.
Strasburger CJ, Buchfelder M, Droste M, Mann K, Stalla GK & Saller B. Experience from the German pegvisomant observational study. Hormone Research 2007 68 70-73.
Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B & Strasburger CJ. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. European Journal of Endocrinology 2007 156 75-82. (Pubitemid 46553905)
T'Sjoen G, Bex M, Maiter D, Velkeniers B & Abs R. Health-related quality of life in acromegalic subjects: data from AcroBel, the Belgian registry on acromegaly. European Journal of Endocrinology 2007 157 411-417. (Pubitemid 350018443)
Neggers SJ, de Herder WW, Janssen JA, Feelders RA & van der Lely AJ. Combined treatment for acromegaly with long-acting somatostatin analogues and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. European Journal of Endocrinology 2009 160 529-533.
Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de HerderWW & van der Lely AJ. Long-term efficacy and safety of combined treatment of somatostatin analogues and pegvisomant in acromegaly. Journal of Clinical Endocrinology and Metabolism 2007 92 4598-4601.
Jimenez C, Burman P, Abs R, Clemmons DR, Drake WM, Hutson KR, Messig M, Thorner MO, Trainer PJ & Gagel RF. Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials. European Journal of Endocrinology 2008 159 517-523.
Neggers SJ, van Aken MO, de HerderWW, Feelders RA, Janssen JA, Badia X,Webb SM & van der Lely AJ. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. Journal of Clinical Endocrinology and Metabolism 2008 93 3853-3859.
